Mesothelioma Therapy Chemotherapy for Mesothelioma 2

Question 1

What is the most common dose-limiting toxicity of pemetrexed in mesothelioma treatment?

Accepted Answer

Myelosuppression (neutropenia)

Answer

Myelosuppression, particularly neutropenia, is the most common dose-limiting toxicity of pemetrexed, requiring careful monitoring of blood counts.

Question 2

Cisplatin-based chemotherapy requires adequate pretreatment hydration primarily to prevent which toxicity?

Accepted Answer

Nephrotoxicity (kidney damage)

Answer

Cisplatin is highly nephrotoxic, and aggressive IV hydration before and after administration is required to protect kidney function.

Question 3

Which chemotherapy drug combination was approved for second-line mesothelioma in the US after initial chemotherapy failure?

Accepted Answer

Nivolumab + ipilimumab

Answer

Nivolumab combined with ipilimumab gained FDA approval for first-line mesothelioma treatment and is also used in subsequent lines after chemotherapy failure.

Question 4

What is the purpose of corticosteroid premedication before pemetrexed infusion?

Accepted Answer

To prevent skin rash

Answer

Dexamethasone premedication is given before pemetrexed to prevent the skin rash that commonly occurs without prophylaxis.

Question 5

In neoadjuvant chemotherapy for mesothelioma, when is chemotherapy administered relative to surgery?

Accepted Answer

Before surgery

Answer

Neoadjuvant chemotherapy is administered before surgery to shrink the tumor and assess chemosensitivity before planned surgical resection.

Mesothelioma Therapy Practice Test

Mesothelioma Therapy Practice Test

Mesothelioma Therapy Chemotherapy for Mesothelioma 2